Neuroprotective Drugs

Neuroprotective Drugs Market Outlook

The global neuroprotective drugs market is projected to reach approximately USD 12 billion by 2035, with a compound annual growth rate (CAGR) of around 7.5% during the forecast period from 2025 to 2035. This impressive growth can be attributed to the increasing prevalence of neurodegenerative disorders such as Alzheimer's and Parkinson's diseases, which demand effective therapeutic solutions. Furthermore, the rising geriatric population, which is highly susceptible to neurological conditions, adds to the market's demand. In addition, advancements in drug formulations and the growing interest in alternative and complementary therapies are expected to fuel market growth. The rising awareness of preventive healthcare measures and the potential of neuroprotective drugs to delay disease progression further contribute to the market expansion.

Growth Factor of the Market

The neuroprotective drugs market is experiencing robust growth due to several key factors. Firstly, the increasing incidence of age-related neurological disorders is driving demand, as the global population ages and the prevalence of conditions like Alzheimer's and Parkinson's rises. Secondly, advancements in research and development technologies are leading to innovative drug formulations that enhance efficacy and safety profiles. Additionally, there is a growing trend toward preventative healthcare, with more individuals and healthcare providers recognizing the importance of neuroprotection in maintaining cognitive health. The rise of personalized medicine is also influencing this market, allowing for tailored treatments based on individual patient needs and genetic profiles. Lastly, the expansion of distribution channels, including online pharmacies, has improved accessibility for patients, further boosting market growth.

Key Highlights of the Market

• The neuroprotective drugs market is projected to reach USD 12 billion by 2035, growing at a CAGR of 7.5%.
• Rising prevalence of neurodegenerative diseases, particularly among the aging population, is a significant driver.
• Innovations in drug research and formulations are enhancing treatment options and efficacy.
• Growing awareness regarding preventative healthcare measures is influencing market dynamics positively.
• Expansion of online pharmacy distribution channels is improving product accessibility for consumers.

By Product Type

Chemical Neuroprotective Drugs:

Chemical neuroprotective drugs dominate the market due to their established efficacy in treating various neurological conditions. These drugs work by targeting specific biochemical pathways that lead to neuronal injury and degeneration. Their applications span across a variety of neurodegenerative diseases, making them a cornerstone in neuroprotection. The development of new chemical entities continues to enhance treatment protocols, with ongoing research focusing on improving their pharmacokinetic and pharmacodynamic profiles. Their widespread prescription in clinical settings is supported by a robust body of clinical evidence, rendering them highly trusted among healthcare professionals.

Herbal Neuroprotective Drugs:

Herbal neuroprotective drugs are gaining popularity as natural alternatives to synthetic medications. These products, derived from various plant sources, are believed to offer neuroprotective benefits with fewer side effects. The growing interest in holistic health and natural remedies has spurred research into the efficacy of plants such as Ginkgo Biloba and Bacopa Monnieri for cognitive health. Clinical studies are increasingly validating their benefits, which include improved neuronal health and cognitive function. This segment is expected to witness significant growth as more consumers seek environmentally friendly and sustainable treatment options.

Nutraceutical Neuroprotective Drugs:

Nutraceutical neuroprotective drugs encompass dietary supplements that are believed to provide health benefits beyond basic nutrition. Ingredients such as omega-3 fatty acids have garnered attention for their neuroprotective properties, particularly in reducing inflammation and oxidative stress in the brain. This segment appeals to health-conscious consumers who are looking to supplement their diets to enhance cognitive function and overall brain health. Increased awareness of the role of nutrition in brain health is likely to drive the growth of this segment, as more individuals incorporate these products into their daily routines.

Biologic Neuroprotective Drugs:

Biologic neuroprotective drugs represent a newer frontier in the treatment of neurological disorders. These drugs, often derived from living organisms, include monoclonal antibodies and other biologics that target specific neural pathways to offer protection against neurodegeneration. Their ability to precisely modulate immune responses in the brain presents unique therapeutic opportunities. As research progresses, biologics are expected to become integral components of treatment regimens for conditions such as multiple sclerosis and amyotrophic lateral sclerosis (ALS), contributing to a more nuanced understanding of neuroprotection.

Others:

This category includes various emerging therapies and compounds that do not fit into the aforementioned classifications. Innovations in biotechnology and pharmaceutical research are leading to the discovery of novel neuroprotective agents, which may offer unique mechanisms of action or target specific patient demographics. This segment is marked by continuous evolution, as researchers explore synergies between existing neuroprotective drugs and new therapeutic approaches. The growing interest in personalized medicine could also lead to breakthroughs in this area, enhancing treatment options for patients with specific neurological conditions.

By Application

Alzheimer's Disease:

Alzheimer's disease remains a significant focus within the neuroprotective drugs market, driven by its high prevalence among the elderly population. Therapeutic strategies aimed at slowing cognitive decline and preserving neuronal function are crucial, as there is currently no cure for this progressive disorder. Neuroprotective drugs targeting amyloid-beta plaques and tau tangles are in the research spotlight, with ongoing clinical trials assessing their effectiveness. The urgency to address the growing Alzheimer's patient population has prompted increased investment in drug development, leading to a surge in innovative treatment options.

Parkinson's Disease:

Parkinson's disease is another key application area for neuroprotective drugs, characterized by motor and non-motor symptoms that significantly impact patients' quality of life. Neuroprotective agents aim to alleviate symptoms and slow disease progression by protecting dopaminergic neurons from degeneration. The use of existing medications along with neuroprotective therapies is being explored in clinical settings, enhancing patient management strategies. As new research uncovers the underlying mechanisms of Parkinson's disease, the market for targeted neuroprotective drugs is expected to expand, offering hope for better treatment outcomes.

Multiple Sclerosis:

Multiple sclerosis (MS) is an autoimmune disorder that affects the central nervous system, leading to significant neurological impairment. Neuroprotective drugs play a vital role in managing MS by modulating immune responses and protecting nerve cells from damage. As understanding of the pathophysiology of MS improves, there is potential for the development of more effective neuroprotective therapies that address both the inflammatory and neurodegenerative components of the disease. This area of research is poised for growth, with increasing patient awareness and demand for effective treatment options driving interest in neuroprotective drugs.

Stroke:

Stroke is a leading cause of long-term disability, highlighting the importance of neuroprotective drugs in both acute and rehabilitative care. Neuroprotective agents aim to minimize brain damage during ischemic events and facilitate recovery post-stroke. This application is increasingly pertinent as the global incidence of stroke rises, necessitating effective therapeutic interventions. Research is ongoing to identify and validate new neuroprotective compounds that can be administered promptly to improve patient outcomes. The growing recognition of the need for immediate treatment options is expected to bolster the market for neuroprotective drugs in the context of stroke management.

Others:

This category includes various other applications of neuroprotective drugs that may address less common neurological conditions or focus on broader neurological health. As research expands, new applications for existing neuroprotective agents are being discovered, potentially leading to shifts in market dynamics. The exploration of neuroprotection in relation to traumatic brain injury (TBI) and other less-defined conditions is an area of interest, fostering innovation and diversifying the scope of neuroprotective treatments available to healthcare providers and patients.

By Distribution Channel

Hospitals:

Hospitals remain a primary distribution channel for neuroprotective drugs, as they serve as the front line for acute medical care. The presence of neurologists and specialists in hospital settings facilitates the prescription of neuroprotective medications, particularly for conditions requiring immediate intervention, such as stroke or acute exacerbations of neurodegenerative diseases. The comprehensive care provided in hospitals, including access to advanced diagnostic tools and monitoring, ensures that patients receive appropriate neuroprotective therapies tailored to their specific needs. This channel is expected to grow as healthcare systems continue to prioritize neurological health.

Retail Pharmacies:

Retail pharmacies play a crucial role in the distribution of neuroprotective drugs, offering convenient access for patients managing chronic neurological conditions. The ability to purchase medications locally fosters better adherence to treatment regimens, as patients can easily obtain prescriptions without the need for hospital visits. Additionally, the growing trend of pharmacist-led counseling and patient education in retail settings supports optimal medication management. As the demand for neuroprotective drugs increases, retail pharmacies are expanding their offerings to include a wider range of both prescription and over-the-counter neuroprotective agents.

Online Pharmacies:

The rise of online pharmacies has revolutionized the way neuroprotective drugs are distributed, providing patients with alternative purchasing options that enhance accessibility. This channel caters to a tech-savvy population seeking convenience, privacy, and potentially lower prices. Online pharmacies also offer the advantage of direct-to-consumer marketing of nutraceutical and herbal neuroprotective products. The COVID-19 pandemic has further accelerated this trend, as patients increasingly turn to online platforms for their pharmaceutical needs. Regulatory frameworks continue to adapt to ensure the safety and security of online medication purchases, paving the way for continued growth in this segment.

Specialty Clinics:

Specialty clinics focused on neurological care are becoming increasingly prominent as a distribution channel for neuroprotective drugs. These clinics often provide comprehensive diagnostic services and tailored treatment plans for patients with specific neurological conditions. The presence of specialists such as neurologists and neuropsychologists allows for a more targeted approach to therapy, including the integration of neuroprotective drugs into holistic treatment plans. As patient demand for specialized care grows, so does the importance of specialty clinics in delivering effective neuroprotective therapies.

Others:

This category encompasses unique distribution channels that may not fit within traditional models, such as telehealth services or integrative health centers. The advent of telemedicine has opened new avenues for prescribing neuroprotective drugs, allowing patients to receive consultations and prescriptions from the comfort of their homes. Integrative health centers, which combine conventional and alternative therapies, also represent a growing niche for neuroprotective products. As the healthcare landscape evolves, these alternative distribution channels may play an increasingly significant role in delivering neuroprotective drugs to patients.

By Ingredient Type

Ginkgo Biloba:

Ginkgo Biloba is one of the most widely studied herbal ingredients for neuroprotection, known for its potential to enhance cognitive function and improve blood circulation. Its antioxidant properties are believed to protect neurons from oxidative stress, making it a popular choice among consumers seeking natural remedies for cognitive decline. Numerous studies have explored its efficacy in treating conditions like Alzheimer's and dementia, contributing to its reputation as a leading ingredient in neuroprotective formulations. As awareness of herbal supplements grows, Ginkgo Biloba is expected to maintain a prominent position in the neuroprotective drugs market.

Omega-3 Fatty Acids:

Omega-3 fatty acids, primarily found in fish oil, are recognized for their neuroprotective effects, which include reducing inflammation and promoting neuronal health. Research suggests that these essential fatty acids play a crucial role in brain function and may help mitigate the risk of neurodegenerative diseases. With growing recognition of the link between diet and cognitive health, omega-3 supplements have gained traction among consumers looking to enhance their brain health proactively. The increasing incorporation of omega-3s into neuroprotective formulations is expected to drive growth in this ingredient segment as more products reach the market.

Curcumin:

Curcumin, the active compound in turmeric, has garnered attention for its neuroprotective and anti-inflammatory properties. Its ability to cross the blood-brain barrier and exert positive effects on brain health makes it a valuable ingredient in neuroprotective formulations. Research indicates that curcumin may help in reducing neuroinflammation and promoting neurogenesis, providing potential therapeutic benefits for conditions such as Alzheimer's and depression. As consumer interest in natural anti-inflammatory agents rises, curcumin is poised to gain momentum in the neuroprotective drugs segment, with increasing incorporation into dietary supplements and functional foods.

Bacopa Monnieri:

Bacopa Monnieri, traditionally used in Ayurvedic medicine, is known for its cognitive-enhancing and neuroprotective properties. Studies suggest that it may improve memory, learning, and overall cognitive function, making it a popular choice for individuals seeking to enhance mental performance. Its potential to support neuronal function and protect against neurodegeneration has led to its inclusion in various neuroprotective formulations. The rising trend of adaptogens and herbal supplements for cognitive health is likely to contribute to the growth of Bacopa Monnieri in the neuroprotective drugs market.

Others:

This category includes various novel or emerging ingredients that demonstrate potential neuroprotective effects. Research is ongoing into a range of compounds, including antioxidants and compounds derived from other plant sources, that may offer unique benefits for brain health. As scientific understanding of neuroprotection advances, new ingredients may enter the market, broadening the scope of neuroprotective formulations available to consumers. The diversity of ingredients represents an exciting area for innovation and expansion in the neuroprotective drugs market.

By Region

The neuroprotective drugs market exhibits significant regional variations, influenced by factors such as healthcare infrastructure, population demographics, and disease prevalence. In North America, the market is projected to account for approximately 40% of the global share by 2035, driven by a high incidence of neurodegenerative disorders and a well-established pharmaceutical sector. The increasing focus on research and development, coupled with robust healthcare expenditure in the United States and Canada, supports the growth of this market. Furthermore, the presence of key players and ongoing clinical trials for innovative therapies position North America as a leader in neuroprotective drug development.

In Europe, the neuroprotective drugs market is expected to grow at a CAGR of around 6.8% during the forecast period, owing to the rising elderly population and the prevalence of chronic neurological conditions. Countries like Germany, France, and the UK are key contributors to the market, with a growing emphasis on preventive healthcare and early intervention strategies. The European market benefits from a strong regulatory framework that encourages drug innovation and the inclusion of herbal and nutraceutical products in the therapeutic landscape. The emergence of healthcare initiatives aimed at addressing the needs of patients with neurological disorders further propels market growth in this region.

Opportunities

The neuroprotective drugs market is ripe with opportunities, particularly as research continues to unveil the complexities of neurological disorders. One of the most promising avenues for growth lies in the development of personalized medicine tailored to individual patients based on genetic, environmental, and lifestyle factors. This approach enhances treatment efficacy and allows for more specific targeting of neuroprotective therapies. Additionally, the integration of technology in drug development, such as artificial intelligence and machine learning, offers the potential to accelerate discovery processes and identify novel neuroprotective compounds. The increasing collaboration between pharmaceutical companies and academic institutions is also expected to foster innovation and enhance the pipeline of neuroprotective drugs.

Another significant opportunity arises from the growing consumer interest in natural and herbal remedies for neurological health. As awareness of the benefits of herbal supplements expands, there is a surge in demand for products that incorporate well-researched neuroprotective ingredients such as Ginkgo Biloba and Bacopa Monnieri. This trend paves the way for companies to develop innovative formulations that combine traditional herbal knowledge with modern scientific research. Furthermore, the rise of online pharmacies and e-commerce platforms allows for greater accessibility and distribution of neuroprotective products, enabling companies to reach a broader audience and cater to diverse consumer preferences.

Threats

The neuroprotective drugs market faces several threats that could hinder growth and innovation. One of the primary concerns is the increasing regulatory scrutiny surrounding drug approval processes, particularly for new chemical entities and biological products. Stricter regulations can lead to longer timelines for bringing new therapies to market, potentially slowing down the pace of innovation and reducing the number of available treatment options for patients. Additionally, the high costs associated with research and development, coupled with the financial burdens of bringing a drug to market, can deter companies from investing in neuroprotective drug development, limiting the overall growth of the market.

Furthermore, the prevalence of counterfeit and substandard drugs poses a significant threat to consumers and the integrity of the market. The rise of online pharmacies has made it easier for counterfeit products to enter the supply chain, which can undermine consumer trust and pose risks to patient health. Regulatory bodies are increasingly challenged to ensure the safety and efficacy of neuroprotective drugs in the market. Addressing these concerns requires robust regulatory frameworks and proactive measures to educate consumers about potential risks, ensuring that patients have access to safe and effective neuroprotective therapies.

Competitor Outlook

• Novartis AG
• Roche Holding AG
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• AbbVie Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Amgen Inc.
• H. Lundbeck A/S
• Neurocrine Biosciences, Inc.
• Biogen Inc.
• Mylan N.V.
• AstraZeneca PLC
• Sanofi S.A.

The competitive landscape of the neuroprotective drugs market is characterized by several key players who are actively engaged in developing and marketing various neuroprotective therapies. The market is dominated by large pharmaceutical companies with extensive research and development capabilities, enabling them to invest in innovative drug formulations and clinical trials. Companies like Novartis and Roche are at the forefront, focusing on cutting-edge research to address unmet therapeutic needs in neurodegenerative diseases. These companies often collaborate with academic institutions and research organizations to foster innovation and bring new therapies to market.

Mid-sized and specialty pharmaceutical companies also play a vital role in the neuroprotective drugs market, often focusing on niche applications or alternative therapies. For example, companies like Biogen and H. Lundbeck specialize in treatments for specific neurological conditions, including Alzheimer's and multiple sclerosis. These firms are agile and adept at responding to emerging trends, such as the increasing demand for herbal and nutraceutical neuroprotective products. Their ability to innovate and adapt quickly positions them favorably in a competitive environment.

As the market continues to evolve, strategic partnerships, mergers, and acquisitions are likely to shape the competitive landscape. Companies are increasingly looking to expand their portfolios by acquiring smaller firms with promising drug candidates or unique technologies. This trend enhances their competitive advantage and allows for a broader range of neuroprotective products to be offered to consumers. The emphasis on personalized medicine and innovative delivery mechanisms is also driving competitive dynamics, with companies striving to differentiate themselves through unique value propositions and improved patient outcomes.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Mylan N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Biogen Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Novartis AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Pfizer Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Sanofi S.A.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 AstraZeneca PLC
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 H. Lundbeck A/S
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Roche Holding AG
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Johnson & Johnson
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Merck & Co., Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Bristol-Myers Squibb Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Neurocrine Biosciences, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Neuroprotective Drugs Market, By Application
    • 6.1.1 Alzheimer's Disease
    • 6.1.2 Parkinson's Disease
    • 6.1.3 Multiple Sclerosis
    • 6.1.4 Stroke
    • 6.1.5 Others
  • 6.2 Neuroprotective Drugs Market, By Product Type
    • 6.2.1 Chemical Neuroprotective Drugs
    • 6.2.2 Herbal Neuroprotective Drugs
    • 6.2.3 Nutraceutical Neuroprotective Drugs
    • 6.2.4 Biologic Neuroprotective Drugs
    • 6.2.5 Others
  • 6.3 Neuroprotective Drugs Market, By Ingredient Type
    • 6.3.1 Ginkgo Biloba
    • 6.3.2 Omega-3 Fatty Acids
    • 6.3.3 Curcumin
    • 6.3.4 Bacopa Monnieri
    • 6.3.5 Others
  • 6.4 Neuroprotective Drugs Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Specialty Clinics
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Neuroprotective Drugs Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Neuroprotective Drugs market is categorized based on

By Product Type

• Chemical Neuroprotective Drugs
• Herbal Neuroprotective Drugs
• Nutraceutical Neuroprotective Drugs
• Biologic Neuroprotective Drugs
• Others

By Application

• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Stroke
• Others

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics
• Others

By Ingredient Type

• Ginkgo Biloba
• Omega-3 Fatty Acids
• Curcumin
• Bacopa Monnieri
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Novartis AG
• Roche Holding AG
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• AbbVie Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Amgen Inc.
• H. Lundbeck A/S
• Neurocrine Biosciences, Inc.
• Biogen Inc.
• Mylan N.V.
• AstraZeneca PLC
• Sanofi S.A.